Next Generation Anti-Infectives that Mimic Natural Human Antimicrobial Peptides
Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented low molecular weight drug candidates that destroy SARS-CoV-2, the COVID virus, as well as other viruses and infectious pathogens (including fungal and bacterial pathogens). Maxwell's first-in-class CLAROMER™ brand drug discovery platform mimics natural human immune system antimicrobial and antiviral peptides.
Maxwell Biosciences has benefitted from over $35M of non-dilutive grants and awards from governments around the world to validate their science and technology, including studies by US Govt-funded labs confirming that Maxwell's lead drug candidate has direct virucidal action against Herpes virus (HSV-1) and SARS-CoV-2, the COVID virus. Additionally, live mouse safety data at Texas A&M show Maxwell's drugs benefit from a tissue-safe toxicology profiles, and live mouse studies from the Baylor College of Medicine show breakthrough fungicidal action with CLAROMER™ brand compounds against lethal fungal infections of the upper-respiratory tract. These findings support the expected safety and effectiveness of Maxwell's “multi-asset, multi-target” anti-infectives drug platform. Maxwell's drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics and a broad spectrum of evolving infectious pathogens. Maxwell is raising funds for advanced preclinical and human trials.
Location: United States, Texas, Austin
Employees: 11-50
Total raised: $10.8M
Founded date: 2016
Investors 3
Date | Name | Website |
- | LoftyInc C... | loftyinc.v... |
13.04.2023 | Keiretsu F... | keiretsufo... |
- | LoftyInc C... | loftyincca... |
Funding Rounds 1
Date | Series | Amount | Investors |
10.03.2022 | Seed | $10.8M | - |
Mentions in press and media 3
Date | Title | Description | Source |
10.03.2022 | Maxwell Biosciences Grabs $10.8M Seed Round | AUSTIN, TX, Maxwell Biosciences today announced that it has closed an oversubscribed $10.8 million... | vcnewsdail... |
10.03.2022 | Maxwell Biosciences Raises $10.8M in Seed Funding Round | Maxwell Biosciences, an Austin, TX-based preclinical stage drug platform company, raised $10.8M in S... | finsmes.co... |
09.04.2021 | David Evans Shaw Backs Maxwell Biosciences | David Evans Shaw Maxwell Biosciences, an Austin, Texas-based developer of next generation virucides,... | finsmes.co... |